U.S. markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8200+0.0516 (+6.72%)
At close: 04:00PM EDT
0.8199 -0.00 (-0.01%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close0.7684
Bid0.8200 x 4000
Ask0.8200 x 1000
Day's Range0.7620 - 0.8700
52 Week Range0.6200 - 11.1800
Avg. Volume1,727,520
Market Cap43.673M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-2.1010
Earnings DateAug 24, 2022 - Aug 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RDHL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Redhill Biopharma Ltd.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • American City Business Journals

    Raleigh drugmaker slashes workforce as biotech downturn deepens

    The drugmaker is cutting one-third of its U.S. commercial workforce as part of a plan to save $50 million. The move comes as the biotech industry sees cuts across the board as the highs of the pandemic fade away.

  • Benzinga

    RedHill Biopharma Shares Trading Higher On Improved Q1 Profitability

    View more earnings on RDHLSee more from BenzingaThe Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows PromiseDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga does not provide investment advice. All rights reserved.

  • PR Newswire

    RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first quarter 2022 financial results and operational highlights, targeting positive cash from operations1 to start during H2/22 and recent implementation of a comprehensive cost reduction plan, expected to generate operational cost savings of approximately $50 million over the next 18 months.